Results 121 to 130 of about 6,343 (174)
Some of the next articles are maybe not open access.
Gastroenterology Nursing, 1992
Asacol (mesalamine) is a delayed release pH-sensitive, polymer-coated, oral preparation of 5-ASA which releases the drug in the terminal ileum and colon for the treatment of mildly to moderately active ulcerative colitis. Treatment modalities using Asacol appear to be an alternative for sulfasalazine-sensitive patients as well as potential first-line ...
openaire +2 more sources
Asacol (mesalamine) is a delayed release pH-sensitive, polymer-coated, oral preparation of 5-ASA which releases the drug in the terminal ileum and colon for the treatment of mildly to moderately active ulcerative colitis. Treatment modalities using Asacol appear to be an alternative for sulfasalazine-sensitive patients as well as potential first-line ...
openaire +2 more sources
Gastroenterology Nursing, 1993
Pentasa (mesalamine) is a newly released oral 5-aminosalicylic acid capsule marketed by Marion Merrel Dow Inc., for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis. Ulcerative colitis is a chronic inflammatory disease and the most common form of inflammatory bowel disease, which is a debilitating and ...
openaire +2 more sources
Pentasa (mesalamine) is a newly released oral 5-aminosalicylic acid capsule marketed by Marion Merrel Dow Inc., for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis. Ulcerative colitis is a chronic inflammatory disease and the most common form of inflammatory bowel disease, which is a debilitating and ...
openaire +2 more sources
The Association of Mesalamine With Kidney Disease
Advances in Chronic Kidney Disease, 2020The package inserts for products containing 5-aminosalicylic acid, or mesalamine, include the following language regarding the risk of adverse kidney effects: "renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and rarely renal failure, has been reported in patients given products such as mesalamine ...
Avinash, Adiga, David S, Goldfarb
openaire +2 more sources
Mesalamine in Ulcerative Colitis
DICP, 1991Sulfasalazine has been used for many years in the management of ulcerative colitis. As many as 20 percent of patients treated with it experience intolerable adverse effects usually attributed to its sulfapyridine component. The other active component is 5-aminosalicylic acid (5-ASA); the only 5-ASA enema preparation currently available in the U.S.
J M, Fitzgerald, T D, Marsh
openaire +2 more sources
Mesalamine-Induced Granulomatous Hepatitis
American Journal of Gastroenterology, 1999A 42-yr-old man with ulcerative colitis was admitted for investigation of prolonged fever associated with cholestatic liver tests. Endoscopic retrograde cholangiopancreatography demonstrated a normal biliary tree, and liver biopsy showed granulomata.
M, Braun +4 more
openaire +2 more sources
American Journal of Gastroenterology, 2014
Poor adherence to mesalamine is common and driven by a combination of lifestyle and behavioral factors, as well as health beliefs. We sought to develop a valid tool to identify barriers to patient adherence and predict those at risk for future nonadherence.A 10-item survey was developed from patient-reported barriers to adherence.
Moss, Alan +7 more
openaire +4 more sources
Poor adherence to mesalamine is common and driven by a combination of lifestyle and behavioral factors, as well as health beliefs. We sought to develop a valid tool to identify barriers to patient adherence and predict those at risk for future nonadherence.A 10-item survey was developed from patient-reported barriers to adherence.
Moss, Alan +7 more
openaire +4 more sources
MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations
Digestive and Liver DiseaseMedical therapy is the cornerstone of ulcerative colitis (UC) management and aims to induce and maintain remission. In case of mild-to-moderate UC, mesalamine (5-ASA) is the first-line option. 5-ASA requires local release at the level of the inflamed mucosa to exert its therapeutic action.
Ferdinando, D'Amico +3 more
openaire +2 more sources
Reviews in gastroenterological disorders, 2006
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral
openaire +1 more source
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral
openaire +1 more source
Connecticut medicine, 2010
Lung toxicity associated with 5-aminosalicylate (5-ASA) agents is very rare. We report the case of a 48-year-old man with ulcerative colitis who developed progressive shortness of breath while taking oral mesalamine. Chest imaging revealed a ground glass appearance in patchy areas distributed throughout the lung. He had a restrictive ventilatory defect
Neha, Jain +2 more
openaire +1 more source
Lung toxicity associated with 5-aminosalicylate (5-ASA) agents is very rare. We report the case of a 48-year-old man with ulcerative colitis who developed progressive shortness of breath while taking oral mesalamine. Chest imaging revealed a ground glass appearance in patchy areas distributed throughout the lung. He had a restrictive ventilatory defect
Neha, Jain +2 more
openaire +1 more source
Multicenter survey on mesalamine intolerance in patients with ulcerative colitis
Journal of Gastroenterology and Hepatology (Australia), 2021Akiko Fujiwara +2 more
exaly